Your browser is no longer supported. Please, upgrade your browser.
TCDA [NASD]
Tricida, Inc.
Index- P/E- EPS (ttm)-5.37 Insider Own1.70% Shs Outstand50.12M Perf Week-9.87%
Market Cap346.93M Forward P/E- EPS next Y-3.91 Insider Trans-8.41% Shs Float48.81M Perf Month-9.52%
Income-268.10M PEG- EPS next Q-1.12 Inst Own91.60% Short Float8.72% Perf Quarter-22.58%
Sales- P/S- EPS this Y-53.40% Inst Trans-0.01% Short Ratio3.31 Perf Half Y-57.39%
Book/sh3.21 P/B2.19 EPS next Y26.50% ROA-69.30% Target Price13.00 Perf Year-79.82%
Cash/sh6.44 P/C1.09 EPS next 5Y- ROE-125.60% 52W Range3.74 - 39.02 Perf YTD-0.28%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-81.98% Beta-
Dividend %- Quick Ratio7.00 Sales past 5Y- Gross Margin- 52W Low87.97% ATR0.49
Employees195 Current Ratio7.00 Sales Q/Q- Oper. Margin- RSI (14)43.50 Volatility6.14% 5.72%
OptionableYes Debt/Eq1.20 EPS Q/Q-73.60% Profit Margin- Rel Volume0.43 Prev Close7.21
ShortableYes LT Debt/Eq1.11 EarningsNov 09 AMC Payout- Avg Volume1.29M Price7.03
Recom2.70 SMA20-5.15% SMA50-2.87% SMA200-56.18% Volume556,711 Change-2.50%
Sep-29-20Resumed JP Morgan Underweight $8
Aug-25-20Downgrade Goldman Buy → Neutral $25 → $10
Jun-27-19Initiated Goldman Buy $48
May-24-19Initiated Needham Buy $50
Jul-23-18Initiated JP Morgan Neutral $34
Jul-23-18Initiated Goldman Neutral $32
Jan-15-21 12:45PM  
12:00PM  
11:30AM  
11:00AM  
11:00AM  
06:12AM  
Jan-14-21 10:00PM  
05:20PM  
04:00PM  
02:43PM  
12:00PM  
12:00PM  
11:00AM  
Jan-13-21 08:00PM  
05:27PM  
04:00PM  
04:00PM  
02:33PM  
01:00PM  
11:45AM  
11:00AM  
11:00AM  
06:30AM  
12:00AM  
Jan-12-21 02:00PM  
01:00PM  
12:50PM  
12:30PM  
12:05PM  
11:30AM  
11:00AM  
Jan-11-21 03:00PM  
02:15PM  
01:00PM  
12:30PM  
12:00PM  
11:15AM  
10:57AM  
09:33AM  
09:05AM  
08:00AM  
08:00AM  
Jan-10-21 10:25AM  
Jan-09-21 07:15PM  
Jan-08-21 04:00PM  
02:35PM  
01:31PM  
01:15PM  
12:05PM  
12:00PM  
11:15AM  
10:40AM  
10:00AM  
Jan-07-21 10:28PM  
10:19PM  
09:00PM  
08:29PM  
06:59PM  
06:11PM  
05:00PM  
03:36PM  
11:00AM  
11:00AM  
Jan-06-21 11:30PM  
11:30PM  
06:30PM  
04:30PM  
Dec-16-20 03:51PM  
Dec-09-20 07:23AM  
Dec-08-20 04:05PM  
Dec-07-20 04:05PM  
Dec-05-20 10:23AM  
Dec-01-20 09:22PM  
Nov-30-20 08:33PM  
Nov-24-20 08:33PM  
Nov-20-20 08:44PM  
Nov-15-20 11:02AM  
Nov-11-20 08:19PM  
Nov-09-20 07:00PM  
04:05PM  
Nov-07-20 09:22PM  
Nov-05-20 08:55PM  
Nov-04-20 08:30PM  
Nov-01-20 10:52AM  
Oct-30-20 08:30PM  
Oct-29-20 06:58PM  
04:35PM  
07:30AM  
Oct-28-20 04:00PM  
Oct-09-20 11:00AM  
Sep-29-20 08:00PM  
08:56AM  
Sep-11-20 02:08PM  
Sep-10-20 12:25PM  
Sep-08-20 02:55PM  
Sep-04-20 05:30PM  
Sep-02-20 12:55PM  
Sep-01-20 11:45PM  
Aug-31-20 08:52PM  
09:12AM  
Tricida, Inc., a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). The company has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis. Tricida, Inc. was founded in 2013 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KLAERNER GERRITPresident and CEOJan 14Sale7.181,65511,883507,993Jan 15 04:32 PM
KLAERNER GERRITPresident and CEOJan 13Sale7.4115,035111,409509,648Jan 15 04:32 PM
KLAERNER GERRITPresident and CEOJan 12Sale7.659,82175,131524,683Jan 13 04:38 PM
KLAERNER GERRITPresident and CEOJan 11Sale7.4921,489160,953534,504Jan 12 04:31 PM
COUFAL SANDRA IDirectorDec 14Sale7.9050,000395,000172,609Dec 15 05:46 PM
McKague RobertEVP, General CounselDec 11Buy7.6210,00076,20010,000Dec 23 05:34 PM
Parker Geoffrey M.CFO and EVPDec 10Buy6.7815,000101,70040,000Dec 10 07:46 PM
KLAERNER GERRITPresident and CEOJul 15Sale26.334,000105,32025,323Jul 16 07:30 PM
KLAERNER GERRITPresident and CEOJul 01Sale27.154,000108,600547,321Jul 02 04:57 PM
KLAERNER GERRITPresident and CEOJun 15Sale25.974,000103,86929,323Jun 16 08:14 PM
KLAERNER GERRITPresident and CEOJun 01Sale26.234,000104,920551,321Jun 03 04:39 PM
KLAERNER GERRITPresident and CEOMay 15Sale31.564,000126,22033,323May 19 07:07 PM
Parker Geoffrey M.Chief Fin. Officer and EVPMay 12Buy30.912,74284,76695,000May 12 08:45 PM
Parker Geoffrey M.Chief Fin. Officer and EVPMay 11Buy30.0232,258968,43792,258May 12 08:45 PM
Otto Dawn ParsellEVP, Clinical DevelopmentMay 08Option Exercise3.033,0009,0991,692May 12 08:38 PM
Otto Dawn ParsellEVP, Clinical DevelopmentMay 08Sale31.983,00095,940255May 12 08:38 PM
Otto Dawn ParsellEVP, Clinical DevelopmentMay 05Option Exercise1.941,2502,4211,053May 07 05:33 PM
Otto Dawn ParsellEVP, Clinical DevelopmentMay 05Sale30.141,25037,680255May 07 05:33 PM
KLAERNER GERRITPresident and CEOMay 01Sale27.984,000111,906555,321May 04 05:34 PM
Otto Dawn ParsellEVP, Clinical DevelopmentApr 29Option Exercise2.823,0008,4501,999Apr 30 04:33 PM
Otto Dawn ParsellEVP, Clinical DevelopmentApr 29Sale31.983,00095,940255Apr 30 04:33 PM
Otto Dawn ParsellEVP, Clinical DevelopmentApr 28Option Exercise1.681,2502,1001,505Apr 30 04:33 PM
Otto Dawn ParsellEVP, Clinical DevelopmentApr 28Sale29.981,25037,475255Apr 30 04:33 PM
KLAERNER GERRITPresident and CEOApr 15Sale27.474,000109,89137,323Apr 16 08:05 PM
KLAERNER GERRITPresident and CEOApr 06Sale24.224,00096,880559,321Apr 08 04:34 PM
KLAERNER GERRITPresident and CEOMar 16Sale23.914,00095,64041,323Mar 18 04:09 PM
Parker Geoffrey M.Chief Fin. Officer and EVPMar 10Buy29.465,000147,30055,000Mar 11 05:10 PM
HEJLEK EDWARD JEVP, General Counsel & Secy.Mar 02Option Exercise0.9610,0009,60028,953Mar 04 07:36 PM
Otto Dawn ParsellEVP, Clinical DevelopmentMar 02Option Exercise2.484,25010,5503,249Mar 04 07:38 PM
HEJLEK EDWARD JEVP, General Counsel & Secy.Mar 02Sale31.6610,000316,61619,153Mar 04 07:36 PM
KLAERNER GERRITPresident and CEOMar 02Sale31.534,000126,120563,321Mar 04 07:33 PM
Otto Dawn ParsellEVP, Clinical DevelopmentMar 02Sale31.844,250135,316255Mar 04 07:38 PM
KLAERNER GERRITPresident and CEOFeb 18Sale36.104,000144,40045,323Feb 20 04:42 PM
Stahl WilhelmChief Tech Officer & Sr. VPFeb 05Option Exercise1.6850084015,306Feb 06 05:07 PM
Stahl WilhelmChief Tech Officer & Sr. VPFeb 05Sale38.9150019,45514,806Feb 06 05:07 PM
HEJLEK EDWARD JSVP, General Counsel & Secy.Feb 03Option Exercise0.9610,0009,60027,022Feb 05 09:29 PM
Otto Dawn ParsellSr VP, Clinical DevelopmentFeb 03Option Exercise2.484,25010,5503,249Feb 05 09:31 PM
Otto Dawn ParsellSr VP, Clinical DevelopmentFeb 03Sale36.864,250156,668255Feb 05 09:31 PM
HEJLEK EDWARD JSVP, General Counsel & Secy.Feb 03Sale36.4210,000364,16919,153Feb 05 09:29 PM
KLAERNER GERRITPresident and CEOFeb 03Sale36.334,000145,330567,321Feb 05 09:27 PM